View Older Stories View More Recent Stories

Dec 21, 2020 06:17AM Athersys (ATHX) and UTHealth Begin Patient Enrollment in Phase 2 Trial Evaluating MultiStem Cell Therapy in Trauma
Dec 21, 2020 06:00AM UTHealth in Houston and Athersys Announce Commencement of Patient Enrollment in a Phase 2 Trial Evaluating MultiStem® Cell Therapy in Trauma
Nov 16, 2020 06:05AM Athersys (ATHX) Announces Ms. Katherine Kalin, Ms. Jane Wasman and Mr. Baiju R. Shah to Board
Nov 16, 2020 06:00AM Athersys Announces Three Appointments to Board of Directors
Nov 9, 2020 04:05PM Athersys Reports Third Quarter 2020 Results and Provides Corporate Update
Oct 8, 2020 01:17PM Athersys to Host Third Quarter Financial Results Call
Sep 23, 2020 06:10AM Athersys (ATHX) Announces FDA Grants RMAT Designation to MultiStem Cell Therapy for the Treatment of Acute Respiratory Distress Syndrome
Sep 23, 2020 06:00AM FDA Grants RMAT Designation to MultiStem Cell Therapy for the Treatment of Acute Respiratory Distress Syndrome
Aug 10, 2020 04:00PM Athersys Reports Second Quarter 2020 Results
Jul 20, 2020 02:00PM Athersys to Host Second Quarter Financial Results Call
May 18, 2020 06:00AM Athersys Announces Upcoming Presentations at the International Society of Cell and Gene Therapy Virtual Conference
May 7, 2020 04:05PM Athersys Reports First Quarter 2020 Results
May 5, 2020 06:22AM Athersys (ATHX) Begins Patient Enrollment in MACOVIA Study, a Pivotal Phase 2/3 Trial Evaluating MultiStem Cell Therapy for COVID-19 Induced ARDS
May 5, 2020 06:00AM  Athersys Announces Commencement of Patient Enrollment in the MACOVIA Study, a Pivotal Phase 2/3 Trial Evaluating MultiStem® Cell Therapy for COVID-19 Induced ARDS
May 1, 2020 06:13AM Athersys (ATHX), UH Cleveland Open 1st Clinical Site for MACOVIA Study, Pivotal Phase 2/3 Study Evaluating MultiStem Cell Therapy for COVID-19 Induced ARDS
May 1, 2020 06:00AM Athersys and University Hospitals Cleveland Medical Center Announce Activation of the First Clinical Site for the MACOVIA Study, a Pivotal Phase 2/3 Study Evaluating MultiStem® Cell Therapy for COVID
Apr 29, 2020 02:47PM Athersys to Present at the Bank of America Merrill Lynch Virtual Healthcare Conference on May 14
Apr 21, 2020 08:00AM Athersys to Host First Quarter Financial Results Call
Apr 15, 2020 06:01AM Athersys (ATHX) Reports FDA Approval to Begin Phase 2 Trial Evaluating MultiStem Cell Therapy in Trauma Patients
Apr 15, 2020 06:00AM FDA Authorizes Initiation of a Phase 2 Trial Evaluating MultiStem® Cell Therapy in Trauma Patients
Apr 15, 2020 06:00AM FDA Authorizes Initiation of a Phase 2 Trial Evaluating MultiStem® Cell Therapy in Trauma Patients
Apr 13, 2020 06:07AM Athersys (ATHX) Reports FDA Approves Initiation of Pivotal Clinical Trial Evaluating MultiStem Cell Therapy in Patients With COVID-19 Induced ARDS
Apr 13, 2020 06:00AM FDA Authorizes Athersys to Initiate a Pivotal Clinical Trial Evaluating MultiStem® Cell Therapy in Patients With COVID-19 Induced Acute Respiratory Distress Syndrome
Mar 30, 2020 06:00AM HEALIOS K.K. Increases Investment in Athersys by Fully Exercising Warrant to Acquire Additional Shares
Mar 19, 2020 06:00AM Athersys Names Maia Hansen Senior Vice President, Operations and Supply Chain
Mar 16, 2020 04:05PM Athersys Announces Financial Results for Fourth Quarter and Full Year 2019
Feb 10, 2020 08:00AM Athersys to Host Year-End 2019 Financial Results Call
Feb 3, 2020 06:00AM Athersys Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Jan 15, 2020 06:02AM Athersys (ATHX) Announces Ivor Macleod as CFO
Jan 15, 2020 06:00AM Athersys Names Ivor Macleod Chief Financial Officer
Jan 14, 2020 06:09AM Athersys (ATHX) Announces Update on 1-Yr ARDS Study Data
Jan 14, 2020 06:00AM Athersys Provides Update on One-Year ARDS Study Data
Nov 14, 2019 06:08AM Athersys (ATHX) Granted Orphan Designation for Acute Respiratory Distress Syndrome Clinical Program
Nov 14, 2019 06:00AM Healios Receives Notification of Orphan Designation for Acute Respiratory Distress Syndrome Clinical Program
Nov 6, 2019 04:05PM Athersys Reports Third Quarter 2019 Results
Aug 7, 2019 04:05PM Athersys Reports Second Quarter 2019 Results
May 8, 2019 04:05PM Athersys Reports First Quarter 2019 Results
Mar 14, 2019 05:04PM Athersys Announces Financial Results for Fourth Quarter and Full Year 2018
Jan 23, 2019 06:06AM Athersys (ATHX) Reports Positive Results from Exploratory Clinical Study of MultiStem Cell Therapy for Treatment of Acute Respiratory Distress Syndrome
Jan 23, 2019 06:00AM Athersys Announces Positive Results From Its Exploratory Clinical Study of MultiStem® Cell Therapy for Treatment of Acute Respiratory Distress Syndrome (ARDS)
Dec 17, 2018 06:05AM Athersys (ATHX) Reports Extension of HEALIOS K.K. Exclusive Period to Negotiate Option for Multistem Therapy License for Indications in China
Dec 17, 2018 06:00AM Healios Agrees to Make Payment to Extend Exclusive Period for Negotiating an Option for a License to Multistem® Therapy for Indications in China
Nov 6, 2018 04:05PM Athersys Reports Third Quarter 2018 Results
Oct 9, 2018 04:00PM Athersys to Host Third Quarter Financial Results Call
Sep 24, 2018 06:00AM Athersys to Present at 2018 Cell & Gene Meeting on the Mesa
Aug 7, 2018 04:05PM Athersys Reports Second Quarter 2018 Results
Aug 3, 2018 06:00AM Athersys Makes Important Leadership Hire to Carry Out Its Manufacturing Strategy
Jul 31, 2018 06:16AM Athersys (ATHX) Reports Enrollment of First Patient in Masters-2 Phase 3 Study of Multistem Treatment for Ischemic Stroke
Jul 31, 2018 06:00AM Athersys Announces Enrollment of First Patient in Masters-2 Phase 3 Study of Multistem® Treatment for Ischemic Stroke
Jul 10, 2018 04:00PM Athersys to Host Second Quarter Financial Results Call
View More Recent Stories View Older Stories